LON:NCYT Novacyt (NCYT) Share Forecast, Price & News GBX 40.10 -1.78 (-4.24%) (As of 04:34 PM ET) Add Compare Share Share Today's Range 40.10▼ 42.6550-Day Range 39.45▼ 5852-Week Range 38.20▼ 179.95Volume36,933 shsAverage Volume193,305 shsMarket Capitalization£28.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About Novacyt (LON:NCYT) StockNovacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.Read More Receive NCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter. Email Address NCYT Stock News HeadlinesMay 26, 2023 | actusnews.comPublication of Annual Report and AGM votingJanuary 30, 2023 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): DHSC Claim Update – Trial Date ListedJune 8, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>January 26, 2023 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group") Full Year 2022 Trading UpdateDecember 7, 2022 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): Non-Executive Director ChangeDecember 6, 2022 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of genesig® COVID-19 3G PCR Test in the UK Under CTDA LegislationNovember 10, 2022 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): Directorate ChangeOctober 26, 2022 | proactiveinvestors.comNovacyt gains UK approval for its multiplex PCR test for detection of winter virusesJune 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.October 26, 2022 | proactiveinvestors.comNovacyt approved for COVID and winter viruses PCR testOctober 10, 2022 | thetimes.co.ukYour three-minute digest - The TimesOctober 10, 2022 | marketscreener.comNovacyt Faces $150 Million Legal Claim For Inconsistent COVID-19 Testing Results In UK - Marketscreener.comOctober 9, 2022 | thetimes.co.ukNovacyt subject to legal claim after 'troubling' Covid test results - The TimesOctober 6, 2022 | businesswire.comOutlook on the High-Resolution Melting Analysis Global Market to 2027 - Featuring Agilent Technologies, Azura Genomics, Illumina and Novacyt Among Others - ResearchAndMarkets.com - Business WireOctober 1, 2022 | seekingalpha.comNovacyt S.A. 2022 Q2 - Results - Earnings Call Presentation (OTCMKTS:NVYTF) - Seeking AlphaSeptember 29, 2022 | morningstar.co.ukEARNINGS UPDATES: Volvere says interim performance... - MorningstarSeptember 29, 2022 | marketwatch.comNovacyt 1H Pretax Loss Narrowed Despite Major Revenue Decline - MarketWatchSeptember 29, 2022 | businesswire.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 Results - Business WireSeptember 29, 2022 | finance.yahoo.comNovacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 ResultsSeptember 21, 2022 | prnewswire.comRapid Plasma Reagin Test Market to observe USD 46.28 Mn incremental growth -- Driven by increasing incidence of syphilis - PR NewswireAugust 31, 2022 | law360.comUK Gov't Sues COVID-19 Test Designer For £135M - Law360August 12, 2022 | finance.yahoo.comGlobal Organ Transplant Diagnostics Market to 2031 - Featuring Abbott Laboratories, ARUP Laboratories, BAG Health Care and bioMerieux Among Others - Yahoo FinanceAugust 10, 2022 | businesswire.comOutlook on the Organ Transplant Diagnostics Global Market to 2031 - High Demand for Molecular Diagnostic Tests is Driving Growth - ResearchAndMarkets.com - Business WireAugust 6, 2022 | morningstar.co.ukTRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim - MorningstarAugust 4, 2022 | marketwatch.comNovacyt Launches New Covid-19 PCR Assays - MarketWatchAugust 4, 2022 | businesswire.comLaunch of Novacyt's first fully lyophilised PROmate® assays - Business WireJuly 28, 2022 | lse.co.ukTRADING UPDATES: Scottish American outperforms; Amte picks Dundee | Financial News - London South EastSee More Headlines NCYT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:NCYT CUSIPN/A CIKN/A Webwww.novacyt.com Phone33 1 39 46 51 04FaxN/AEmployees174Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-22,200,000.00 Net Margins-122.29% Pretax MarginN/A Return on Equity-17.27% Return on Assets-6.06% Debt Debt-to-Equity Ratio0.76 Current Ratio5.25 Quick Ratio4.46 Sales & Book Value Annual Sales£21.04 million Price / Sales1.35 Cash FlowGBX 69.09 per share Price / Cash Flow0.58 Book ValueGBX 163 per share Price / Book0.25Miscellaneous Outstanding Shares70,630,000Free FloatN/AMarket Cap£28.32 million OptionableNot Optionable Beta-2.22 Key ExecutivesMr. James Martin McCarthy (Age 57)CFO, Acting CEO, Company Sec. & Director Comp: $361.66kBryan CloseChief Operations OfficerMs. Wendy KarbanGroup HR Mang.Mr. David FranksChief HR OfficerPaul OladimejiGroup Head of R&DMr. Gérald UlrichChief Exec. Officer of Bus. Devel.Mr. Steve GibsonGroup Financial ControllerMore ExecutivesKey Competitors4D pharmaLON:DDDDOndine BiomedicalLON:OBICollagen Solutions plc (COS.L)LON:COSBiodexa PharmaceuticalsLON:MTPHDestiny PharmaLON:DESTView All CompetitorsInsidersJames WakefieldBought 7,000 shares on 7/7/2022Total: £819,000.00 ($117.00/share)View All Insider Transactions NCYT Stock - Frequently Asked Questions How have NCYT shares performed in 2023? Novacyt's stock was trading at GBX 113 on January 1st, 2023. Since then, NCYT shares have decreased by 64.5% and is now trading at GBX 40.10. View the best growth stocks for 2023 here. What other stocks do shareholders of Novacyt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Biocept (BIOC), Ecolab (ECL), genedrive (GDR), Geron (GERN), Immunic (IMUX), Tiziana Life Sciences (TILS), Verastem (VSTM), VYNE Therapeutics (VYNE), Antero Midstream (AM) and Aileron Therapeutics (ALRN). What is Novacyt's stock symbol? Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT." How do I buy shares of Novacyt? Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Novacyt's stock price today? One share of NCYT stock can currently be purchased for approximately GBX 40.10. How much money does Novacyt make? Novacyt (LON:NCYT) has a market capitalization of £28.32 million and generates £21.04 million in revenue each year. The company earns £-22,200,000.00 in net income (profit) each year or GBX (0.32) on an earnings per share basis. How many employees does Novacyt have? The company employs 174 workers across the globe. How can I contact Novacyt? The official website for the company is www.novacyt.com. The company can be reached via phone at 33 1 39 46 51 04. This page (LON:NCYT) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.